Search Within

Jedd D Wolchok

  1. "Annals of Oncology"
Formats
  1. Meeting Abstract (26)
  2. Journal Article (8)
Groups
  1. Department of Medicine (34)
  2. GSK Faculty (34)
  3. Melanoma and Immunotherapeutics Service (34)
  4. Solid Tumor Oncology Division (34)
  5. Melanoma Disease Management Team (4)
  6. Thoracic Oncology (4)

More Groups

People
  1. Matthew Hellmann (4)
  2. Jamie Chaft (3)
  3. Charles Rudin (2)
  4. Hira Rizvi (2)
  5. Margaret Callahan (2)
  6. Michael Postow (2)

More People

Years
  1. 2021 (1)
  2. 2020 (2)
  3. 2019 (2)
  4. 2018 (2)
  5. 2017 (4)
  6. 2016 (6)

More Years

Publications
  1. Annals of Oncology (34)
Publishers
  1. Oxford University Press (34)

Results (34)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma
    Meeting Abstract

    Shoushtari, A. N.; Olszanski, A. J.; Nyakas, M.; Hornyak, T. J.; Wolchok, J. D.; Levitsky, V.; Møller, A. S.; Kuryk, L.; Handeland, K. R.; Jäderberg, M.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Long-term safety profile of pembrolizumab monotherapy and relationship with clinical outcome: A pooled analysis of patients with advanced melanoma
    Meeting Abstract

    Hamid, O.; Joshua, A. M.; Hwu, W. J.; Ribas, A.; Weber, J.; Daud, A. S.; Hodi, F. S.; Wolchok, J. D.; Mitchell, T. C.; Hersey, P.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO + IPI) or NIVO alone
    Meeting Abstract

    Robert, C.; Long, G. V.; Larkin, J.; Wolchok, J. D.; Hassel, J. C.; Schadendorf, D.; Hodi, F. S.; Lebbé, C.; Grob, J. J.; Grossmann, K.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma
    Meeting Abstract

    Larkin, J. M. G.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Rutkowski, P.; Lao, C.; Cowey, C. L.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
    Journal Article

    Hamid, O.; Robert, C.; Daud, A.; Hodi, F. S.; Hwu, W. J.; Kefford, R.; Wolchok, J. D.; Hersey, P.; Joseph, R.; Weber, J. S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)
    Meeting Abstract

    Hodi, F. S.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Rutkowski, P.; Cowey, C. L.; Lao, C.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: A proposal for quantitative immune-related pathologic response criteria (irPRC)
    Journal Article

    Cottrell, T. R.; Thompson, E. D.; Forde, P. M.; Stein, J. E.; Duffield, A. S.; Anagnostou, V.; Rekhtman, N.; Anders, R. A.; Cuda, J. D.; Illei, P. B.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone
    Meeting Abstract

    Robert, C.; Larkin, J.; Ascierto, P. A.; Long, G. V.; Hassel, J. C.; Schadendorf, D.; Hodi, F. S.; Lebbé, C.; Grob, J. J.; Grossmann, K.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • LKB1 loss is a novel genomic predictor of de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma
    Meeting Abstract

    Skoulidis, F.; Hellman, M. D.; Awad, M.; Gainor, J. F.; Rizvi, H.; Carter, B.; Denning, W. L.; Villalobos, P.; Parra, E. R.; Elamin, Y. Y.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067)
    Meeting Abstract

    Grob, J. J.; Schadendorf, D.; Wagstaff, J.; Márquez-Rodas, I.; Lebbé, C.; Ascierto, P. A.; Hodi, F. S.; Grossmann, K.; Hassel, J. C.; Walker, D.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save